USP18 and myeloid sarcoma: However, the finding is in contrary to the clinical observation that lower USP18 expression correlates with higher MS severity [16], indicating that mutations of USP18 in other cell populations, rather than CD4+ T cells, might be responsible for MS pathogenesis.